bpc 157 lyme disease A Functional Medicine Guide to The Immunology of Alpha‐Gal Syndrome:

Pillar 2: Therapeutic Peptides as the Targeted Repair Crew While LDN works on systemic immune balance, peptide therapy offers a more targeted approach to healing

You've got a win

Initial treatment for patients with neurological involvement follows British National Formulary (BNF) guidance: Hydroxocobalamin 1 mg intramuscularly on alternate days for approximately 2-3 weeks (or until no further improvement) Maintenance therapy then consists of hydroxocobalamin 1 mg intramuscularly every two months Hydroxocobalamin is preferred over cyanocobalamin in the UK due to superior retention and fewer injections required

Moderate risk individuals include those over 40 with minor family history, those slightly behind on screening, or those using BPC-157 for moderate rather than severe healing needs